CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 24 enrolled
Drug / intervention
Clindamycin 300 mg capsule +1 moredrug
Likely dose
Clindamycin 300 mg capsulefrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00836004
NCT00836004Phase 1Completed

Randomized, 2-Way Crossover, Bioequivalence Study of Clindamycin 300 mg Capsules and Cleocin Hcl Administered as 1 x 300 mg Capsule in Healthy Subjects Under Fed Conditions

Teva Pharmaceuticals USA·interventional·Posted Feb 4, 2009·Updated Aug 19, 2024

In Brief

A Phase 1 clinical trial evaluating Clindamycin 300 mg capsule and Cleocin HCl 300 mg capsules for Healthy. Completed, enrolled 24 participants across 1 site.

Detailed Summary

The objective of this study is to compare the rate and extent of absorption of clindamycin 300 mg capsules (test) versus Cleocin HCl (reference, administered as 1 x 300 mg capsule under fed conditions.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesCanada
Collaborators--

Timeline

Phase 1CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 4, 2009
Enrollment StartNov 1, 2003
Primary CompletionNov 1, 2003
TodayJul 2, 2026
Enrollment to primary: 0 daysPosted 17.4 years ago

Interventions

Clindamycin 300 mg capsuledrug

1 x 300 mg

Cleocin HCl 300 mg capsulesdrug

1 x 300 mg